KEYNOTE-033: Phase 3 study of pembrolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (NSCLC)

被引：0
作者：
Zhou, C. [1 ]
Caglevic, C. [2 ]
Zhou, J. [3 ]
Wang, B. [4 ]
Wang, K. [5 ]
Ge, J. [6 ]
Zhou, Y. [6 ]
Piperdi, B. [7 ]
Ma, Z. [8 ]
机构：
[1] Shanghai Pulm Hosp, Dept Oncol, Shanghai, Peoples R China
[2] FALP, Dept Oncol, Santiago, Chile
[3] Zhejiang Univ, Hosp 1, Dept Respirat, Hangzhou, Zhejiang, Peoples R China
[4] Subei Peoples Hosp, Dept Oncol, Yangzhou, Jiangsu, Peoples R China
[5] Zhejiang Univ, Hosp 2, Dept Respirat, Hangzhou, Zhejiang, Peoples R China
[6] MSD China, Oncol, Shanghai, Peoples R China
[7] Merck & Co Inc, Oncol, Kenilworth, NJ USA
[8] Henan Canc Hosp, Dept Oncol, Zhengzhou, Henan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
466TiP
引用
收藏
页码：143 / 143
页数：1
相关论文
共 50 条
  • [21] Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non-Small-Cell Lung Cancer
    Okamoto, Isamu
    Miyazaki, Masaki
    Takeda, Masayuki
    Terashima, Masaaki
    Azuma, Koichi
    Hayashi, Hidetoshi
    Kaneda, Hiroyasu
    Kurata, Takayasu
    Tsurutani, Junji
    Seto, Takashi
    Hirai, Fumihiko
    Konishi, Koichi
    Sarashina, Akiko
    Yagi, Nobutaka
    Kaiser, Rolf
    Nakagawa, Kazuhiko
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 346 - 352
  • [22] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
    Rittmeyer, Achim
    Barlesi, Fabrice
    Waterkamp, Daniel
    Park, Keunchil
    Ciardiello, Fortunato
    von Pawel, Joachim
    Gadgeel, Shirish M.
    Hida, Toyoaki
    Kowalski, Dariusz M.
    Dols, Manuel Cobo
    Cortinovis, Diego L.
    Leach, Joseph
    Polikoff, Jonathan
    Barrios, Carlos
    Kabbinavar, Fairooz
    Frontera, Osvaldo Aren
    De Marinis, Filippo
    Turna, Hande
    Lee, Jong-Seok
    Ballinger, Marcus
    Kowanetz, Marcin
    He, Pei
    Chen, Daniel S.
    Sandler, Alan
    Gandara, David R.
    LANCET, 2017, 389 (10066) : 255 - 265
  • [23] Phase II Study of Cetuximab, Docetaxel, and Gemcitabine in Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer
    Spigel, David R.
    Greco, F. Anthony
    Thompson, Dana S.
    Webb, Charles
    Rubinsak, James
    Inhorn, Roger C.
    Reeves, James, Jr.
    Vazquez, Elizabeth R.
    Lane, Cassie M.
    Burris, Howard A., III
    Hainsworth, John D.
    CLINICAL LUNG CANCER, 2010, 11 (03) : 198 - 203
  • [24] A randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with previously treated advanced non-small-cell lung cancer
    Sekine, Ikuo
    Ichinose, Yukito
    Nishiwaki, Yutaka
    Yamamoto, Nobuyuki
    Tsuboi, Masahiro
    Nakagawa, Kazuhiko
    Shinkai, Tetsu
    Jiang Haiyi
    Tamura, Tomohide
    Fukuoka, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S339 - S340
  • [25] Efficacy of docetaxel in non-small-cell lung cancer patients previously treated with paltinum-containing chemotherapy
    Robinet, G
    Thomas, P
    Pérol, M
    Vergnenègre, A
    Lena, H
    Taytard, A
    Paillotin, D
    Bessa, EH
    Schuller-Lebeau, MP
    REVUE DES MALADIES RESPIRATOIRES, 2000, 17 (01) : 83 - 89
  • [26] Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer
    Hanna, Nasser
    Lilenbaum, Rogerio
    Ansari, Rafat
    Lynch, Thomas
    Govindan, Ramaswamy
    Jaenne, Pasi A.
    Bonomi, Philip
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (33) : 5253 - 5258
  • [27] Phase I study of oral nintedanib combined with docetaxel in previously treated Japanese patients with advanced non-small cell lung cancer (NSCLC)
    Okamoto, I.
    Miyazaki, M.
    Takeda, M.
    Azuma, K.
    Hayashi, H.
    Seto, T.
    Konishi, K.
    Sarashina, A.
    Kaiser, R.
    Nakagawa, K.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S830 - S831
  • [28] SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)
    Borghaei, H.
    Johnson, M. L.
    Garon, E. B.
    He, K.
    Planchard, D.
    Reck, M.
    Popat, S.
    Herbst, R. S.
    Leal, T. A.
    Dumoulin, D.
    De Marinis, F.
    Reynolds, C. H.
    Theelen, W. S. M. E.
    Percent, I.
    Calderon, V. Gutierrez
    Flandin, A. C. Madroszyk
    Shazer, R. L.
    Yan, X.
    Harrigan, R.
    Peters, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1308 - S1308
  • [29] Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China
    Gong, Jinhong
    Su, Dan
    Shang, Jingjing
    Xu, Shan
    Tang, Lidan
    Sun, Zhiqiang
    Liu, Guangjun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [30] Phase III study of vinflunine versus docetaxel in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with a platinum containing regimen
    Ramlau, Rodryg
    Bennouna, Jaafar
    Tan, Eng Huat
    Biesma, Bonne
    Santoro, Armando
    Boni, Corrado
    Klein, Helmut
    Lesniewski, Krzysztof
    Mesia, Ricard
    Gatzemeier, Urlich
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S317 - S318
12345